With all the news generated recently about the obesity risks (which may lead to elevated cardio-vascular risks) from Risperdal, Abilify and Zyprexa, et al. -- given the very common long-term use of these sorts of anti-psychotic drugs -- I thought it worthwhile to highlight the view of many analysts, on Asenapine (to be tradenamed "Saphris"), per a Forbes article, out this morning.
Note that this does not bode well for moving the drug over to treating Alzheimers-related dementia:
. . . ."Even if approval occurs, the commercial outlook for Saphris seems challenging," wrote Sanford Berstein analyst Tim Anderson in a note to investors. "The drug would be entering a crowded atypical antipsychotic category where a benchmark product -- Johnson & Johnson's Risperal -- recently went generic, and Schering has no commercial presence in this area, meaning it would need to build infrastructure to market Saphris." Anderson added that his expectations for the drug's approval had been low until this point. . . .
Good luck with that, Dr. Koestler.